Summary & Overview
HCPCS J7615: Levalbuterol Inhalation Solution, Compounded Unit Dose 0.5 mg
HCPCS Level II code J7615 designates compounded levalbuterol inhalation solution supplied as unit-dose 0.5 mg for use with durable medical equipment. The code is used when levalbuterol is prepared as a compounded solution and administered through DME nebulizers, making it relevant for acute bronchodilator therapy delivered in home or outpatient environments. Nationally, accurate coding of compounded inhalation products affects pharmacy billing, DME coordination, and coverage determinations across public and commercial payers.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for levalbuterol unit-dose use, typical service settings, and the payer landscape that influences coverage and claims processing. The publication outlines common billing modifiers and administrative considerations, summarizes benchmark and reimbursement concepts where available, and notes gaps when input data is not provided. The content is intended to help payers, providers, and billing professionals understand the purpose of J7615, the settings where it is used, and the administrative elements commonly associated with compounded inhalation solutions supplied for DME administration.
Billing Code Overview
HCPCS Level II code J7615 describes Levalbuterol, inhalation solution, compounded product, administered through DME, unit dose, 0.5 mg. This code represents a pharmacy-supplied, compounded inhalation bronchodilator solution formulated as single-use unit doses of levalbuterol at 0.5 mg strength.
Service Type: Pharmaceutical administration via durable medical equipment (DME)
Typical Site of Service: Home or outpatient setting using DME nebulizer devices
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with acute bronchospasm due to conditions such as acute asthma exacerbation or reactive airways disease who requires inhaled short-acting beta-agonist therapy delivered via a durable medical equipment nebulizer at home or in an outpatient infusion/respiratory clinic. The clinical workflow begins with a clinician diagnosing bronchospasm (history, exam, and peak flow or pulse oximetry as indicated), prescribing J7615 (levalbuterol 0.5 mg unit dose compounded for nebulization) for use with DME nebulizer equipment, and documenting indication, dose, frequency, and route. A pharmacy or compounding service prepares unit-dose inhalation solution labeled for the patient. The medication is supplied with or billed through the durable medical equipment provider when administered through DME; administration may occur in the patient’s home by the patient/caregiver or in an outpatient respiratory clinic with nursing documentation of administration, response, and any adverse effects. Follow-up documentation includes symptom response, need for additional bronchodilator doses, and any changes to controller therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (not a standard CMS modifier for Medicare billing) | Not typically appended; use per payer guidance when no other modifier applies. |
| Increased procedural services | Use when unusually high complexity or time is documented for services associated with administration or preparation beyond standard compounding.